Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $24.77 Consensus PT from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Hold” from the twenty-seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.7727.

A number of research firms recently commented on SRPT. Oppenheimer reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Loop Capital set a $25.00 target price on Sarepta Therapeutics in a research report on Tuesday, March 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Yousif Capital Management LLC grew its position in Sarepta Therapeutics by 1.9% in the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock valued at $541,000 after acquiring an additional 481 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Sarepta Therapeutics by 7.8% in the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 636 shares during the last quarter. Arizona State Retirement System grew its position in Sarepta Therapeutics by 2.8% in the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock valued at $504,000 after acquiring an additional 717 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its position in Sarepta Therapeutics by 6.1% in the third quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 728 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 744 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 2.1%

SRPT stock opened at $15.31 on Wednesday. The company has a market cap of $1.62 billion, a PE ratio of -15.95, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21. The business has a 50-day simple moving average of $19.23 and a 200 day simple moving average of $19.75. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $38.09. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The business had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.Sarepta Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.42) earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post 3.99 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.